ReviewThe pharmacogenomics journal2002
Pharmacogenetics of the arylamine N-acetyltransferases.
Review in The pharmacogenomics journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Pharmacogenetic association betweenBioscience reports · 2019Pooled it
- Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis.Journal of cancer research and clinical oncology · 2011Pooled it
- N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients.BMC medical genetics · 2006Pooled it
- N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.BMC medical genetics · 2006Pooled it
- Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.European journal of clinical pharmacology · 2007Trial
- Carnosic Acid Attenuates TNF-α-Induced Insulin Resistance by Regulating Mitochondrial Function in 3T3-L1 Adipocytes.Current issues in molecular biology · 2026Article
- Untargeted Proteomics Profiling of Liver and Plasma in Fed and Fasted Liver-Specific Glycogen Storage Disease Type Ia (GSD Ia) Mice: Toward Potential Protein Biomarkers.Journal of inherited metabolic disease · 2026Article
- Pharmacogenomic heterogeneity ofAnnals of medicine · 2025Observational
- Human xenobiotic metabolism proteins have full-length and split homologs in the gut microbiome.G3 (Bethesda, Md.) · 2025Article
- Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases.Clinical pharmacology and therapeutics · 2025Article
- The N-Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case-Control Study.Pharmacology research & perspectives · 2025Article
- Association of the cytochrome P450 and arylamine N-acetyltransferase gene polymorphisms with the incidence of head and neck cancer in Polish population.International journal of occupational medicine and environmental health · 2023Article
- Human N-acetyltransferase 2 (Frontiers in pharmacology · 2023Article
- LncRNA-Associated Genetic Etiologies Are Shared between Type 2 Diabetes and Cancers in the UAE Population.Cancers · 2022Article
- Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population.Human genomics · 2022Review
- Acetyl coenzyme A kinetic studies onFrontiers in pharmacology · 2022Article
- Investigations on detoxification mechanisms of novel para-phenylenediamine analogues through N-acetyltransferase 1 (NAT-1).Archives of toxicology · 2022Article
- Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients.The pharmacogenomics journal · 2021Article
- Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.Methods in molecular biology (Clifton, N.J.) · 2021Article
- NAT2 Gene rs1041983 is Associated with Anti-Tuberculosis Drug Induced Hepatotoxicity Among Pediatric Tuberculosis in Bandung, Indonesia.The application of clinical genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The arylamine N-acetyltransferases (NATs) are involved in the metabolism of a variety of different compounds that we are exposed to on a daily basis. Many drugs and chemicals found in the environment, such as those in cigarette smoke, car exhaust fumes and in foodstuffs, can be either detoxified by NATs and eliminated from the body or bioactivated to metabolites that have the potential to cause toxicity and/or cancer. NATs have been implicated in some adverse drug reactions and as risk factors for several different types of cancers. As a result, the levels of NATs in the body have important consequences with regard to an individual's susceptibility to certain drug-induced toxicities and cancers. This review focuses on recent advances in the molecular genetics of the human NATs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.